Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / SCNN1A

SCNN1A

Basics

Aliases:
This biomarker is also known as:
  • Alpha-NaCH,
  • ENaCa,
  • Amiloride-sensitive sodium channel subunit alpha,
  • Nonvoltage-gated sodium channel 1 subunit alpha,
  • SCNEA,
  • SCNN1,
  • Alpha-ENaC,
  • Epithelial Na(+) channel subunit alpha,
  • BESC2,
  • FLJ21883,
  • sodium channel, nonvoltage-gated 1 alpha,
  • ENaCalpha,

View in BioMuta

Description…

SCNN1A, a multi-pass membrane protein belonging to the amiloride-sensitive sodium channel family, is a sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. These channels are heteromeric complexes consisting of 3 subunits: alpha, beta, and gamma; the SCNN1A gene encodes the alpha subunit. SCNN1A mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. It controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception. It is highly expressed in kidney and lung, detected at intermediate levels in pancreas and liver, and at low levels in heart and placenta. Defects in SCNN1A are a cause of autosomal recessive pseudohypoaldosteronism type 1, a rare salt wasting disease resulting from target organ unresponsiveness to mineralocorticoids.

Attributes

QA State: Under Review
Type: Protein
Short Name:
HGNC Name: SCNN1A

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.